Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Poxel : Corporate Presentation - English

share with twitter share with LinkedIn share with facebook
07/07/2020 | 12:24pm EDT

Corporate Presentation

June 2020

1

Disclaimer

Some of the statements contained in this presentation constitute forward-looking statements. Statements that are not historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue" or similar terminology. These statements are based on the Company's current strategy, plans, objectives, assumptions, estimates and projections. Investors should therefore not place undue reliance on those statements. The Company makes no representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Forward-looking statements speak only as of the date that they are made and the Company does not undertake to update any forward-looking statements in light of new information or future events. Forward-looking statements involve inherent risks and uncertainties. The Company cautions that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company has undertaken a full review of the impact of the outbreak on its business. Considering the rapidly evolving situation, the Company is updating this assessment on a regular basis.

The Company anticipates that the COVID-19 pandemic could have a material negative impact on our business operations. The worldwide impact of COVID-19 may notably affect the Company's internal organization and efficiency, particularly in countries where it operates and where confinement measures have been implemented by the authorities. In addition, the deteriorating market conditions may impact the Company's ability to raise additional funding and/or to enter into partnerships. Particularly, delays in the supply of drug substance or drug products, in pre-clinical and/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could potentially have an impact on the Company's development programs. The Company will continue to proactively monitor the situation.

Poxel: A Mid-to-Late Stage Metabolic-Focused Opportunity

  • Global partnerships

  • Novel mechanism with platform expansion

  • Potential for fast-to-market strategy via 505(b)(2) pathway

  • Exploring NASH combinations and rare metabolic indications

  • Cash & equiv. EUR 36.9 million (USD 40.4 million) as of March 31, 2020; subsequently, Poxel announced a capital increase of EUR 17.7M ($19.4M) on May 25, 2020

Metabolic Disease: A Consequence of Overnutrition and Reduced Energy Utilization

IMBALANCES OF ENERGY SUPPLY / DEMAND DRIVE THESE NEGATIVE EFFECTS:

Insulin resistance

Increased lipid storageReduced fat oxidation

Poxel Targets Key Mechanisms that have Distinct Roles in Regulating Cellular Energy Homeostasis

Multiple Entry Points Available to Intervene in Metabolic Diseases

Mitochondrial Pyruvate Carrier (MPC), fuel gate-keeper - inhibition:

AMP-activated Protein Kinase (AMPK), cellular energy sensor - activation: reduces liver fat, increases insulin sensitivity, decreases inflammation

Acetyl

MPC

Co-A

TCA cycle

T

promotes fat utilization, increases

insulin sensitivity, decreases

inflammation

ATP

MITOCHONDRIA

Mitochondrial Respiratory Chain (MRC), cell's energy producing machine - potential to modulate function: improves b-cell function, increases insulin sensitivity, improves endothelial and diastolic dysfunction

Disclaimer

Poxel SA published this content on 24 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 July 2020 15:23:00 UTC


share with twitter share with LinkedIn share with facebook
All news about POXEL
10/21Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Qu..
AQ
10/20POXEL : Corporate Presentation - English
PU
10/20POXEL : Provides Corporate Update and Reports Cash and Revenue for the Third Qua..
BU
10/16Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the Frenc..
AQ
10/15POXEL : Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French..
BU
10/11POXEL : Corporate Presentation - English
PU
10/07POXEL : Corporate Presentation - English
PU
10/02POXEL : Announces Positive Results from Phase 2a NASH Trial with PXL770, an Oral..
AQ
10/01POXEL : Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral..
BU
09/25Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-..
AQ
More news
Financials
Sales 2020 14,7 M 17,4 M 17,4 M
Net income 2020 -28,0 M -33,1 M -33,1 M
Net cash 2020 21,6 M 25,5 M 25,5 M
P/E ratio 2020 -5,90x
Yield 2020 -
Capitalization 175 M 207 M 207 M
EV / Sales 2020 10,4x
EV / Sales 2021 2,55x
Nbr of Employees 51
Free-Float 75,3%
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 18,55 €
Last Close Price 6,15 €
Spread / Highest target 241%
Spread / Average Target 202%
Spread / Lowest Target 168%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Sebastien Bolze Chief Operating Officer & Executive Vice President
Anne Renevot Chief Financial Officer & Executive Vice President
Sophie Hallakou-Bozec Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
POXEL-48.44%212
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.59.09%37 775
BEIGENE, LTD.80.38%27 097